LOGIN  |  REGISTER

HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum

August 15, 2022 | Last Trade: US$2.09 0.00 0.00

HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in a fireside chat during the SVB Securities Virtual Vaccine Forum. HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, HIL-214, will be a topic of discussion.

Fireside chat details:
Date:Thursday, August 18, 2022
Time:3:00 – 3:50 p.m. Eastern Daylight Time (EDT)
Moderator:David Risinger, CFA
HilleVax Participant:Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer

Please contact your SVB Securities representative to view the session

About HilleVax

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Contact:

Shane Maltbie
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-617-213-5054

 


Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page